在临床数据库上对癌症的草药干预措施的当前特征:一个横截面研究
Bo-Young Youn1, Ji-Hyun Kim2, Yong-Kyu Jo2
1Hwasung Medi-Science University, Hwaseong-si, Gyeonggi-do, South Korea.
Integrative cancer therapies
|December 15, 2023
概括
这项研究分析了102项关于癌症草药的临床试验. 大多数试验来自亚洲,由医院赞助,专注于肺癌,乳腺癌和结直肠癌,但需要更强大的试验设计.
科学领域:
- 在瘤学瘤学.
- 药理学 药理学是指药理学的学科.
- 临床研究 临床研究
背景情况:
- 草药在癌症治疗中表现有前途,但临床试验的特征尚不清楚.
- 缺乏对癌症中草药干预的注册临床试验的全面评估.
研究的目的:
- 评估已注册的临床试验的特点,研究用于癌症治疗的草药干预措施.
- 确定草药癌症研究当前格局的趋势和差距.
主要方法:
- 一项横截面研究分析了截至2023年3月26日的主要临床试验注册表 (ClinicalTrials.gov,ISRCTN,中国临床试验注册表,ICTRP) 的数据.
- 使用开发的关键词的高级搜索策略来识别相关的注册试验.
- 从所有可获得的试验中收集信息进行了全面的审查.
主要成果:
- 包括102项临床试验,亚洲 (62.75%) 和医院 (42.16%) 分别是领先的地区和赞助商.
- 主要的试验类型包括随机的,第二阶段的干预性研究,大多数招募的参与者不到100人 (64.71%).
- 大多数试验是在2016年至2023年之间进行的 (53.92%),重点是肺癌,乳腺癌和结直肠癌,尽管在45项已完成的试验中,只有16项有可用的结果.
结论:
- 这项研究提供了第一个在主要数据库中对草药癌症临床试验特征的全面概述.
- 虽然有信息,但这些发现表明需要改进临床试验设计,以支持草药在癌症治疗中的整合.
- 专注于精心设计的试验的进一步研究对于卫生专业人员来说至关重要,以考虑草药作为一种可行的癌症治疗选择.
更多相关视频
13:18Network Pharmacology Prediction and Experimental Validation of Trichosanthes-Fritillaria thunbergii Action Mechanism Against Lung Adenocarcinoma
Published on: March 3, 2023
1.3K
06:24Author Spotlight: Liujunzi Decoction as a Traditional Chinese Treatment for Coloproctitis Cancer
Published on: October 13, 2023
930
相关概念视频
Cancer Prevention
Several factors can increase the risk of cancer in an individual. About 50% of cancer cases can be prevented by adopting a healthy lifestyle, regular exercise, eating healthy, and following a modest cancer prevention diet. Epidemiological studies have consistently shown that populations with vegetable and fruit-rich diets have reduced the incidence of cancer. On the other hand, populations who have a diet rich in animal fat, red meat, junk food, or high calories are predisposed to cancer.
Some...
Some...
Targeted Cancer Therapies
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
There are several types of targeted therapies against specific...
Combination Therapies and Personalized Medicine
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Treatment Resistent Cancers
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Cancer Survival Analysis
Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...
